Pub Date : 2014-12-01DOI: 10.1590/0004-2730000003561
Shan-Shan Liu, Lou Ji-Quan, Ding Ye
{"title":"PTPN2, a potential therapeutic target for type 1 diabetes?","authors":"Shan-Shan Liu, Lou Ji-Quan, Ding Ye","doi":"10.1590/0004-2730000003561","DOIUrl":"https://doi.org/10.1590/0004-2730000003561","url":null,"abstract":"","PeriodicalId":8395,"journal":{"name":"Arquivos brasileiros de endocrinologia e metabologia","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2014-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33007405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objective: Microcalcification is strongly correlated with papillary thyroid cancer. It is not clear whether macrocalcification is associated with malignancy. In this study, we aimed to assess the result of fine needle aspiration biopsies (FNAB) of thyroid nodules with macrocalcifications.
Subjects and methods: We retrospectively evaluated 269 patients (907 nodules). Macrocalcifications were classified as eggshell and parenchymal macrocalcification. FNAB results were divided into four groups: benign, malignant, suspicious for malignancy, and non-diagnostic.
Results: There were 79.9% female and 20.1% male and mean age was 56.9 years. Macrocalcification was detected in 46.3% nodules and 53.7% nodules had no macrocalcification. Parenchymal and eggshell macrocalcification were observed in 40.5% and 5.8% nodules, respectively. Cytologically, malignant and suspicious for malignancy rates were higher in nodules with macrocalcification compared to nodules without macrocalcification (p = 0.004 and p = 0.003, respectively). Benign and non-diagnostic cytology results were similar in two groups (p > 0.05). Nodules with eggshell calcification had higher rate of suspicious for malignancy and nodules with parenchymal macrocalcification had higher rates of malignant and suspicious for malignancy compared to those without macrocalcification (p = 0.01, p = 0.003 and p = 0.007, respectively).
Conclusions: Our findings suggest that macrocalcifications are not always benign and are not associated with increased nondiagnostic FNAB results. Macrocalcification, particularly the parenchymal type should be taken into consideration.
目的:微钙化与甲状腺乳头状癌密切相关。目前尚不清楚大钙化是否与恶性肿瘤有关。在这项研究中,我们的目的是评估细针穿刺活检(FNAB)的结果甲状腺结节大钙化。对象和方法:我们回顾性评估了269例患者(907个结节)。大钙化分为蛋壳大钙化和实质大钙化。FNAB结果分为良性、恶性、疑似恶性和非诊断性四组。结果:女性占79.9%,男性占20.1%,平均年龄56.9岁。46.3%结节存在大钙化,53.7%结节不存在大钙化。结节实质和蛋壳大钙化分别占40.5%和5.8%。在细胞学上,与未发生大钙化的结节相比,伴有大钙化的结节的恶性和可疑恶性发生率更高(p = 0.004和p = 0.003)。两组良性和非诊断性细胞学结果相似(p > 0.05)。蛋壳钙化结节的恶性可疑率高于未发生大钙化的结节(p = 0.01, p = 0.003, p = 0.007),实质大钙化结节的恶性可疑率高于未发生大钙化结节(p = 0.01, p = 0.003, p = 0.007)。结论:我们的研究结果表明,大钙化并不总是良性的,也与非诊断性FNAB结果的增加无关。应考虑大钙化,特别是实质钙化。
{"title":"Evaluation of cytopathological findings in thyroid nodules with macrocalcification: macrocalcification is not innocent as it seems.","authors":"Dilek Arpaci, Didem Ozdemir, Neslihan Cuhaci, Ahmet Dirikoc, Aylin Kilicyazgan, Gulnur Guler, Reyhan Ersoy, Bekir Cakir","doi":"10.1590/0004-2730000003602","DOIUrl":"https://doi.org/10.1590/0004-2730000003602","url":null,"abstract":"<p><strong>Objective: </strong>Microcalcification is strongly correlated with papillary thyroid cancer. It is not clear whether macrocalcification is associated with malignancy. In this study, we aimed to assess the result of fine needle aspiration biopsies (FNAB) of thyroid nodules with macrocalcifications.</p><p><strong>Subjects and methods: </strong>We retrospectively evaluated 269 patients (907 nodules). Macrocalcifications were classified as eggshell and parenchymal macrocalcification. FNAB results were divided into four groups: benign, malignant, suspicious for malignancy, and non-diagnostic.</p><p><strong>Results: </strong>There were 79.9% female and 20.1% male and mean age was 56.9 years. Macrocalcification was detected in 46.3% nodules and 53.7% nodules had no macrocalcification. Parenchymal and eggshell macrocalcification were observed in 40.5% and 5.8% nodules, respectively. Cytologically, malignant and suspicious for malignancy rates were higher in nodules with macrocalcification compared to nodules without macrocalcification (p = 0.004 and p = 0.003, respectively). Benign and non-diagnostic cytology results were similar in two groups (p > 0.05). Nodules with eggshell calcification had higher rate of suspicious for malignancy and nodules with parenchymal macrocalcification had higher rates of malignant and suspicious for malignancy compared to those without macrocalcification (p = 0.01, p = 0.003 and p = 0.007, respectively).</p><p><strong>Conclusions: </strong>Our findings suggest that macrocalcifications are not always benign and are not associated with increased nondiagnostic FNAB results. Macrocalcification, particularly the parenchymal type should be taken into consideration.</p>","PeriodicalId":8395,"journal":{"name":"Arquivos brasileiros de endocrinologia e metabologia","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2014-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1590/0004-2730000003602","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33337743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2014-12-01DOI: 10.1590/0004-2730000003097
Mari Cassol Ferreira, Joana Tozatti, Silvia Maria Fachin, Patricia Pereira de Oliveira, Rosa Ferreira dos Santos, Maria Elisabeth Rossi da Silva
Objectives: The aim of the present study was to evaluate the functional mobility and its relationship to cognitive ability in patients with type 2 diabetes (T2DM), age between 50 and 65 years and under 10 years of diagnosis.
Materials and methods: An observational, analytical and cross-sectional study, involving no diabetic and type 2 diabetic individuals with inadequate glycemic control, selected by convenience sampling. In both groups, were administered structured questionnaire and cognitive assessment with Mini-Mental State Examination (MMSE) and the clock drawing test (CDT), besides assessment of functional mobility by the Timed Up & Go (TUG).
Results: In TUG, DM2 patients presented a mean time of 11.27 seconds versus 9.52 seconds (p = 0.013). The association between cognitive decline and decrease of mobility was positive in individuals with T2DM (p = 0.037). In the subgroup that showed decrease of mobility and associated cognitive decline, 18% were patients with DM2 and 1.6% were individuals without T2DM (p < 0.01).
Conclusions: Patients with T2DM presented worse functional mobility and cognitive performance, supporting the hypothesis that DM2 influence functional mobility and cognitive ability, regardless of neuropathic or vascular complications. These data suggest that hyperglycemia is an aggravating factor in the performance of activities requiring mental functions such as attention, working memory and orientation.
{"title":"[Reduction of functional mobility and cognitive capacity in type 2 diabetes mellitus].","authors":"Mari Cassol Ferreira, Joana Tozatti, Silvia Maria Fachin, Patricia Pereira de Oliveira, Rosa Ferreira dos Santos, Maria Elisabeth Rossi da Silva","doi":"10.1590/0004-2730000003097","DOIUrl":"https://doi.org/10.1590/0004-2730000003097","url":null,"abstract":"<p><strong>Objectives: </strong>The aim of the present study was to evaluate the functional mobility and its relationship to cognitive ability in patients with type 2 diabetes (T2DM), age between 50 and 65 years and under 10 years of diagnosis.</p><p><strong>Materials and methods: </strong>An observational, analytical and cross-sectional study, involving no diabetic and type 2 diabetic individuals with inadequate glycemic control, selected by convenience sampling. In both groups, were administered structured questionnaire and cognitive assessment with Mini-Mental State Examination (MMSE) and the clock drawing test (CDT), besides assessment of functional mobility by the Timed Up & Go (TUG).</p><p><strong>Results: </strong>In TUG, DM2 patients presented a mean time of 11.27 seconds versus 9.52 seconds (p = 0.013). The association between cognitive decline and decrease of mobility was positive in individuals with T2DM (p = 0.037). In the subgroup that showed decrease of mobility and associated cognitive decline, 18% were patients with DM2 and 1.6% were individuals without T2DM (p < 0.01).</p><p><strong>Conclusions: </strong>Patients with T2DM presented worse functional mobility and cognitive performance, supporting the hypothesis that DM2 influence functional mobility and cognitive ability, regardless of neuropathic or vascular complications. These data suggest that hyperglycemia is an aggravating factor in the performance of activities requiring mental functions such as attention, working memory and orientation.</p>","PeriodicalId":8395,"journal":{"name":"Arquivos brasileiros de endocrinologia e metabologia","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2014-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1590/0004-2730000003097","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33337744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2014-12-01DOI: 10.1590/0004-2730000003260
Eda Demir Onal, Serhat Isik, Dilek Berker, Serdar Guler
W e read with great interest the article by Lima-Martínez and cols. (1). They studied the relationship between epicardial adipose tissue (EAT) thickness and plasma levels of adiponectin in Venezuelan patients. And they found a significant association between EAT thickness and both metabolic syndrome components and adiponectin concentration. The authors also reported a strong correlation between left ventricular mass and EAT thickness. The article has important messages. But there are some items to be clarified. Angiotensin II (AII), the major hormone of the renin-angiotensin system, plays an important role in the pathogenesis of hypertension and atherosclerosis. Evidence has suggested that AII impairs insulin sensitivity (2). Hypertensive subjects and animal models have shown improvements in insulin resistance in response to treatment with angiotensin I converting enzyme (ACE) inhibitors or AII type 1 receptor (AT1R) blocker (3). The exact mechanisms for the AII-induced insulin resistance remain largely unknown. But Ran and cols. previously showed that long-term AII infusion decreased the circulating adiponectin concentration without affecting the gene expression in rats, and this may facilitate the development of insulin resistance. And AT1R blocker ameliorated the AII-induced hypoadiponectinemia (4). Left ventricular hypertrophy (LVH) is well known to be associated with increased cardiac risk. Regression of LVH over a period of a few months has been reported with ACE inhibitors and angiotensin receptor blockers (ARBs) (5). Regression of LVH continues gradually over time (three years or more) and may be associated with complete reversal of LVH and other abnormalities induced by hypertension such as left atrial enlargement and diastolic dysfunction (5). Lima-Martínez and cols. mentioned that 16 out of 27 patients in their series were on ACE inhibitor or ARB therapy (1). Considering the above mentioned data, antihypertensive therapy may have influenced left ventricular measurements and plasma levels of adiponectin. For these reasons, the authors have better mentioned this point as a limitation of the study.
{"title":"Angiotensin-II induced insulin resistance.","authors":"Eda Demir Onal, Serhat Isik, Dilek Berker, Serdar Guler","doi":"10.1590/0004-2730000003260","DOIUrl":"https://doi.org/10.1590/0004-2730000003260","url":null,"abstract":"W e read with great interest the article by Lima-Martínez and cols. (1). They studied the relationship between epicardial adipose tissue (EAT) thickness and plasma levels of adiponectin in Venezuelan patients. And they found a significant association between EAT thickness and both metabolic syndrome components and adiponectin concentration. The authors also reported a strong correlation between left ventricular mass and EAT thickness. The article has important messages. But there are some items to be clarified. Angiotensin II (AII), the major hormone of the renin-angiotensin system, plays an important role in the pathogenesis of hypertension and atherosclerosis. Evidence has suggested that AII impairs insulin sensitivity (2). Hypertensive subjects and animal models have shown improvements in insulin resistance in response to treatment with angiotensin I converting enzyme (ACE) inhibitors or AII type 1 receptor (AT1R) blocker (3). The exact mechanisms for the AII-induced insulin resistance remain largely unknown. But Ran and cols. previously showed that long-term AII infusion decreased the circulating adiponectin concentration without affecting the gene expression in rats, and this may facilitate the development of insulin resistance. And AT1R blocker ameliorated the AII-induced hypoadiponectinemia (4). Left ventricular hypertrophy (LVH) is well known to be associated with increased cardiac risk. Regression of LVH over a period of a few months has been reported with ACE inhibitors and angiotensin receptor blockers (ARBs) (5). Regression of LVH continues gradually over time (three years or more) and may be associated with complete reversal of LVH and other abnormalities induced by hypertension such as left atrial enlargement and diastolic dysfunction (5). Lima-Martínez and cols. mentioned that 16 out of 27 patients in their series were on ACE inhibitor or ARB therapy (1). Considering the above mentioned data, antihypertensive therapy may have influenced left ventricular measurements and plasma levels of adiponectin. For these reasons, the authors have better mentioned this point as a limitation of the study.","PeriodicalId":8395,"journal":{"name":"Arquivos brasileiros de endocrinologia e metabologia","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2014-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33007401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2014-12-01DOI: 10.1590/0004-2730000003387
Marcelo Benedito Menezes, Antonio Augusto Tupinambá Bertelli, Mauro Ajaj Saieg, Tales Maciel de Camargo, Antonio José Gonçalves
O carcinoma papilifero da tireoide, o mais comum deste orgao, geralmente se apresenta como lesoes parenquimatosas pequenas e, eventualmente, com metastases cervicais numerosas, raramente volumosas. E descrito um caso raro de uma paciente do genero feminino, 44 anos, com um tumor cervical anterior, nodular e volumoso ha nove anos. Apos o tratamento cirurgico, o anatomopatologico mostrou tratar-se de metastases linfonodais de carcinoma papilifero. O objetivo deste estudo e relatar um caso clinico de apresentacao incomum de carcinoma papilifero da tireoide, de diagnostico inicial dificil e apresentando-se com metastases linfonodais volumosas. Arq Bras Endocrinol Metab. 2014;58(9):967-9 Papillary thyroid carcinoma, the most common type of thyroid cancer is usually presented as small parenchymatous lesions and, eventually, with cervical lymph node metastasis, rarely voluminous. Here we describe a rare case of a 44-year-old woman presenting a visible anterior cervical tumor, nodullary and voluminous, for nine years. After surgical treatment, the anatomical pathology sample revealed that the mass was composed of several cervical lymph node metastatic lesions of a papillary thyroid carcinoma. We report the discovery of an uncommon papillary thyroid carcinoma manifestation, with a difficult initial diagnosis and presenting voluminous lymph node metastases.
{"title":"[Giant metastasis of thyroid papillar carcinoma].","authors":"Marcelo Benedito Menezes, Antonio Augusto Tupinambá Bertelli, Mauro Ajaj Saieg, Tales Maciel de Camargo, Antonio José Gonçalves","doi":"10.1590/0004-2730000003387","DOIUrl":"https://doi.org/10.1590/0004-2730000003387","url":null,"abstract":"O carcinoma papilifero da tireoide, o mais comum deste orgao, geralmente se apresenta como lesoes parenquimatosas pequenas e, eventualmente, com metastases cervicais numerosas, raramente volumosas. E descrito um caso raro de uma paciente do genero feminino, 44 anos, com um tumor cervical anterior, nodular e volumoso ha nove anos. Apos o tratamento cirurgico, o anatomopatologico mostrou tratar-se de metastases linfonodais de carcinoma papilifero. O objetivo deste estudo e relatar um caso clinico de apresentacao incomum de carcinoma papilifero da tireoide, de diagnostico inicial dificil e apresentando-se com metastases linfonodais volumosas. Arq Bras Endocrinol Metab. 2014;58(9):967-9 Papillary thyroid carcinoma, the most common type of thyroid cancer is usually presented as small parenchymatous lesions and, eventually, with cervical lymph node metastasis, rarely voluminous. Here we describe a rare case of a 44-year-old woman presenting a visible anterior cervical tumor, nodullary and voluminous, for nine years. After surgical treatment, the anatomical pathology sample revealed that the mass was composed of several cervical lymph node metastatic lesions of a papillary thyroid carcinoma. We report the discovery of an uncommon papillary thyroid carcinoma manifestation, with a difficult initial diagnosis and presenting voluminous lymph node metastases.","PeriodicalId":8395,"journal":{"name":"Arquivos brasileiros de endocrinologia e metabologia","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2014-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1590/0004-2730000003387","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33007400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2014-12-01DOI: 10.1590/0004-2730000003664
Jakeline Rheinheimer, Luis Henrique Canani, Daisy Crispim
{"title":"PTPN2 gene polymorphisms are associated with type 1 diabetes mellitus in Brazilian subjects?","authors":"Jakeline Rheinheimer, Luis Henrique Canani, Daisy Crispim","doi":"10.1590/0004-2730000003664","DOIUrl":"https://doi.org/10.1590/0004-2730000003664","url":null,"abstract":"","PeriodicalId":8395,"journal":{"name":"Arquivos brasileiros de endocrinologia e metabologia","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2014-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33007406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2014-12-01DOI: 10.1590/0004-2730000003216
Juliana Garcia, Larissa de França, Vivian Ellinger, Mônica Wolff
Atypical presentation forms of hyperthyroidism are always a challenge to the clinician. We present a female patient with the typical symptoms of thyrotoxicosis, without any thionamides treatment before, associated with pancytopenia, which recovered after euthyroidism state was achieved. Although the major cases of pancytopenia in Grave's disease are seen as a complication of antithyroid drugs (thioamides), in this case report the alteration in blood tests was associated with untreated hyperthyroidism. In the literature review, we found 19 case reports between 1981 to 2012, but it has been related to a hypercellular bone marrow with periferic destruction. Our case, however, is about a hypocellular bone marrow without fibrosis or fat tissue replacement, which proceeded with a periferic improvement following thyroid treatment. Although rare, pancytopenia, when present, may develop as an unusual and severe manifestation in untreated subjects.
{"title":"Marrow hypoplasia: a rare complication of untreated Grave's disease.","authors":"Juliana Garcia, Larissa de França, Vivian Ellinger, Mônica Wolff","doi":"10.1590/0004-2730000003216","DOIUrl":"https://doi.org/10.1590/0004-2730000003216","url":null,"abstract":"<p><p>Atypical presentation forms of hyperthyroidism are always a challenge to the clinician. We present a female patient with the typical symptoms of thyrotoxicosis, without any thionamides treatment before, associated with pancytopenia, which recovered after euthyroidism state was achieved. Although the major cases of pancytopenia in Grave's disease are seen as a complication of antithyroid drugs (thioamides), in this case report the alteration in blood tests was associated with untreated hyperthyroidism. In the literature review, we found 19 case reports between 1981 to 2012, but it has been related to a hypercellular bone marrow with periferic destruction. Our case, however, is about a hypocellular bone marrow without fibrosis or fat tissue replacement, which proceeded with a periferic improvement following thyroid treatment. Although rare, pancytopenia, when present, may develop as an unusual and severe manifestation in untreated subjects. </p>","PeriodicalId":8395,"journal":{"name":"Arquivos brasileiros de endocrinologia e metabologia","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2014-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1590/0004-2730000003216","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33337745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2014-12-01DOI: 10.1590/0004-2730000003552
Hea Min Yu, Kang Seo Park, Jae Min Lee
e read the paper by Sevket BALTA and cols. and thanks for your interest in our study entitled “Red Cell Distribution Width in Subclinical Hypothyroidism” (1). As we mentioned in the discussion part, the RDW can be affected by some disease conditions such as recent blood transfusion, renal dysfunction, hepatic dysfunction, anemia related nutritional deficiencies (i.e. iron, vitamin B
{"title":"Response to the letter: Red cell distribution width in subclinical hypothyroidism.","authors":"Hea Min Yu, Kang Seo Park, Jae Min Lee","doi":"10.1590/0004-2730000003552","DOIUrl":"https://doi.org/10.1590/0004-2730000003552","url":null,"abstract":"e read the paper by Sevket BALTA and cols. and thanks for your interest in our study entitled “Red Cell Distribution Width in Subclinical Hypothyroidism” (1). As we mentioned in the discussion part, the RDW can be affected by some disease conditions such as recent blood transfusion, renal dysfunction, hepatic dysfunction, anemia related nutritional deficiencies (i.e. iron, vitamin B","PeriodicalId":8395,"journal":{"name":"Arquivos brasileiros de endocrinologia e metabologia","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2014-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33007404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2014-12-01DOI: 10.1590/0004-2730000003538
Alexander Shinkov, Anna-Maria Borissova, Roussanka Kovatcheva, Iliana Atanassova, Jordan Vlahov, Lilia Dakovska
Objective: The aim of the study was to assess the prevalence and characteristics of metabolic syndrome (MetS) and its elements in relation to TSH in euthyroid subjects.
Materials and methods: In the cross-sectional study, 2,153 euthyroid adults, 47.2 ± 14.5 years (20-94) with no current antithyroid or thyroid replacement therapy were enrolled. All participants filled a questionnaire on past and current morbidities, medication and smoking. Body weight, height, waist circumference, serum TSH, glucose and lipids were measured. The subjects were stratified by quartiles of TSH (QTSH) and the prevalence of the MetS elements was calculated. MetS was determined by the IDF 2005 criteria.
Results: Overweight prevalence was 37.2% (35.2-39.2), obesity in 25.1% (23.3-26.9), abdominal obesity - 61.4% (59.3-63.5), hypertension - 42.1% (38.9-43.1), diabetes/increased fasting glucose - 13.6% (12.1-15), low HDL-cholesterol - 27.6% (25.7-29.5), hypertriglyceridemia - 24.1% (22.3-25.9), MetS - 32.2% (30.2-34.2). MetS was more prevalent in the highest QTSH (34.9%, 30.9-38.9) than the lowest (27%, 23.3-30.9), p < 0.001, as were low HDL-C (32%, 28-35.9 vs. 25%, 21.3-28.7, p < 0.001) and hypertriglyceridemia (26.8%, 23-30.5 vs. 20.4%, 17-23.8, p = 0.015). Each QTSH increased the risk of MetS by 14%, p < 0.001, of hypertriglyceridemia by 20%, p = 0.001 and of low LDL-C by 9%, p = 0.042. Other significant factors for MetS were age, male gender and obesity.
Conclusion: The prevalence of MetS increased with higher QTSH within the euthyroid range, mostly by an increase in the dyslipidemia.
{"title":"The prevalence of the metabolic syndrome increases through the quartiles of thyroid stimulating hormone in a population-based sample of euthyroid subjects.","authors":"Alexander Shinkov, Anna-Maria Borissova, Roussanka Kovatcheva, Iliana Atanassova, Jordan Vlahov, Lilia Dakovska","doi":"10.1590/0004-2730000003538","DOIUrl":"https://doi.org/10.1590/0004-2730000003538","url":null,"abstract":"<p><strong>Objective: </strong>The aim of the study was to assess the prevalence and characteristics of metabolic syndrome (MetS) and its elements in relation to TSH in euthyroid subjects.</p><p><strong>Materials and methods: </strong>In the cross-sectional study, 2,153 euthyroid adults, 47.2 ± 14.5 years (20-94) with no current antithyroid or thyroid replacement therapy were enrolled. All participants filled a questionnaire on past and current morbidities, medication and smoking. Body weight, height, waist circumference, serum TSH, glucose and lipids were measured. The subjects were stratified by quartiles of TSH (QTSH) and the prevalence of the MetS elements was calculated. MetS was determined by the IDF 2005 criteria.</p><p><strong>Results: </strong>Overweight prevalence was 37.2% (35.2-39.2), obesity in 25.1% (23.3-26.9), abdominal obesity - 61.4% (59.3-63.5), hypertension - 42.1% (38.9-43.1), diabetes/increased fasting glucose - 13.6% (12.1-15), low HDL-cholesterol - 27.6% (25.7-29.5), hypertriglyceridemia - 24.1% (22.3-25.9), MetS - 32.2% (30.2-34.2). MetS was more prevalent in the highest QTSH (34.9%, 30.9-38.9) than the lowest (27%, 23.3-30.9), p < 0.001, as were low HDL-C (32%, 28-35.9 vs. 25%, 21.3-28.7, p < 0.001) and hypertriglyceridemia (26.8%, 23-30.5 vs. 20.4%, 17-23.8, p = 0.015). Each QTSH increased the risk of MetS by 14%, p < 0.001, of hypertriglyceridemia by 20%, p = 0.001 and of low LDL-C by 9%, p = 0.042. Other significant factors for MetS were age, male gender and obesity.</p><p><strong>Conclusion: </strong>The prevalence of MetS increased with higher QTSH within the euthyroid range, mostly by an increase in the dyslipidemia.</p>","PeriodicalId":8395,"journal":{"name":"Arquivos brasileiros de endocrinologia e metabologia","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2014-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1590/0004-2730000003538","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33337741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2014-12-01DOI: 10.1590/0004-2730000003492
Bruno Halpern, Marcio Correa Mancini, Alfredo Halpern
Brown adipose tissue, an essential organ for thermoregulation in small and hibernating mammals due to its mitochondrial uncoupling capacity, was until recently considered to be present in humans only in newborns. The identification of brown adipose tissue in adult humans since the development and use of positron emission tomography marked with 18-fluorodeoxyglucose (PET-FDG) has raised a series of doubts and questions about its real importance in our metabolism. In this review, we will discuss what we have learnt since its identification in humans as well as both new and old concepts, some of which have been marginalized for decades, such as diet-induced thermogenesis.
{"title":"Brown adipose tissue: what have we learned since its recent identification in human adults.","authors":"Bruno Halpern, Marcio Correa Mancini, Alfredo Halpern","doi":"10.1590/0004-2730000003492","DOIUrl":"https://doi.org/10.1590/0004-2730000003492","url":null,"abstract":"<p><p>Brown adipose tissue, an essential organ for thermoregulation in small and hibernating mammals due to its mitochondrial uncoupling capacity, was until recently considered to be present in humans only in newborns. The identification of brown adipose tissue in adult humans since the development and use of positron emission tomography marked with 18-fluorodeoxyglucose (PET-FDG) has raised a series of doubts and questions about its real importance in our metabolism. In this review, we will discuss what we have learnt since its identification in humans as well as both new and old concepts, some of which have been marginalized for decades, such as diet-induced thermogenesis.</p>","PeriodicalId":8395,"journal":{"name":"Arquivos brasileiros de endocrinologia e metabologia","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2014-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1590/0004-2730000003492","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33332415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}